MeiraGTx Holdings plc
Key Metrics
- Previous Close
- $8.46
- 52-Week Range
- $6.62 – $15.35
- Market Cap
- $813.12M
- P/E (TTM)
- 9.56
- EPS (TTM)
- 0.87
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.78
- PEG Ratio
- —
- Return on Equity
- 89.50%
- Return on Assets
- 37.47%
- Gross Margin
- 97.20%
- Operating Margin
- 44.84%
- Profit Margin
- 19.48%
- Current Ratio
- 4.63
- Debt/Equity
- 0.62
- Total Debt
- $133.85M
- Free Cash Flow
- $47.40M
- Revenue Growth
- 1074.10%
- Earnings Growth
- —
- Enterprise Value
- $762.46M
Market Snapshot
About
MeiraGTx Holdings is a clinical-stage gene therapy company developing treatments for inherited retinal diseases, neurodegenerative disorders, and xerostomia. The company uses AAV and lentiviral vector technologies to deliver genetic therapies.